

Appendix A

Claim 1- (currently amended):

A method of PDT treatment of cardiovascular indications associated with occlusions of a blood vessel comprising the steps of:

administering a photosensitizer drug other than psoralen compounds; and

delivering intravascular photoactivating light to the blood vessel at an activation wavelength within the range of about 390 to ~~about~~ 610 nm such that the molar extinction coefficient of the photosensitizer drug at the activation wavelength is at least $1000 \text{ L cm}^{-1} \text{ M}^{-1}$.

Claim 2- (previously presented):

The method of claim 1 wherein the photosensitizer drug is texaphyrin or a derivative thereof.

Claim 3 – (previously presented):

The method of claim 2 wherein the photosensitizer drug is lutetium texaphyrin.

Claim 4 – (original):

The method of claim 3 wherein the light is delivered at an activation wavelength within the range of about 457 to about 458 nm.

Claim 5 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a benzoporphyrin or a derivative thereof.

Claim 6 – (original):

The method of claim 5 wherein the light is delivered at an activation wavelength within the range of about 457 to about 458 nm.

Claim 7 – (previously presented):

The method of claim 5 wherein the photosensitizer drug is Visudyne.

Claim 8 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a xanthene or a derivative thereof.

Claim 9 – (original):

The method of claim 8 wherein the photosensitizer drug is Rose Bengal or a derivative thereof.

Claim 10 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is azaporphyrin or a derivative thereof.

Claim 11 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a phthalocyanine or a derivative thereof.

Claim 12 – (original):

The method of claim 1 wherein the photosensitizer drug is a naturally occurring or synthetic porphyrin or a derivative thereof.

Claim 13 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a purpurin or a derivative thereof.

Claim 14 – (original):

The method of claim 1 wherein the photosensitizer drug is a naturally occurring or synthetic chlorin or a derivative thereof.

Claim 15 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a porphycyanine or a derivative thereof.

Claim 16 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is an isomeric porphyrin or a derivative thereof.

Claim 17 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a pentaphyrin or a derivative thereof.

Claim 18 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a sapphyrin or a derivative thereof.

Claim 19 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a phlorin or a derivative thereof.

Claim 20 – (original):

The method of claim 1 wherein the photosensitizer drug is a naturally occurring or synthetic bacteriochlorin or a derivative thereof.

Claim 21 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a benzochlorin or a derivative thereof.

Claim 22 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a hypericin or a derivative thereof.

Claim 23 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is an anthraquinone or a derivative thereof.

Claim 24 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a rhodanol or a derivative thereof.

Claim 25 – (previously presented)

The method of claim 1 wherein the photosensitizer drug is a barbituric acid or a derivative thereof.

Claim 26 – (original):

The method of claim 1 wherein the photosensitizer drug is an expanded porphyrin or a derivative thereof.

Claim 27 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a dipyrromethene or a derivative thereof.

Claim 28 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a coumarin or a derivative thereof.

Claim 29 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is an azo or a derivative thereof.

Claim 30 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is an acridine or a derivative thereof.

Claim 31 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a rhodanine or a derivative thereof.

Claim 32 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is an azine or a derivative thereof.

Claim 33 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a tetrazolium or a derivative thereof.

Claim 34 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a safranine or a derivative thereof.

Claim 35 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is an indocyanine or a derivative thereof.

Claim 36 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is an indigo dye or a derivative thereof.

Claim 37 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a triazine or a derivative thereof.

Claim 38 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a pyrrole derived macrocyclic compound or a derivative thereof.

Claim 39 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a naturally occurring or synthetic isobacteriochlorin or a derivative thereof.

Claim 40 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a naphthalocyanine or a derivative thereof.

Claim 41 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a phenoxazine or a derivative thereof.

Claim 42 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a phenothiazine or a derivative thereof.

Claim 43 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a chaloorganapyrylium or a derivative thereof.

Claim 44 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a triarylmethane or a derivative thereof.

Claim 45 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a rhodamine or a derivative thereof.

Claim 46 – (original):

The method of claim 1 wherein the photosensitizer drug is fluorescein or a derivative thereof.

Claim 47 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a verdin or a derivative thereof.

Claim 48 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is touidine blue or a derivative thereof.

Claim 49 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is methylene blue or a derivative thereof.

Claim 50 – (original):

The method of claim 1 wherein the photosensitizer drug is methylene violet or a derivative thereof.

Claim 51 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is nile blue or a derivative thereof.

Claim 52 – (original):

The method of claim 1 wherein the photosensitizer drug is nile red or a derivative thereof.

Claim 53 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a phenazine or a derivative thereof.

Claim 54 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a pinacyanol or a derivative thereof.

Claim 55 – (original):

The method of claim 1 wherein the photosensitizer drug is a plasmocorinth or a derivative thereof.

Claim 56 - (canceled).

Claim 57 - (currently amended):

A method of PDT treatment of cardiovascular indications associated with occlusions of a blood vessel comprising the steps of:

administering a photosensitizer drug; and

delivering a photoactivating light to the blood vessel with a intravascular light delivering device at an activation wavelength within the range of about 440 to ~~about~~ 610 nm such that the molar extinction coefficient of said drug at the activation wavelength is at least $1000 \text{ L cm}^{-1} \text{ M}^{-1}$.

Claim 58 - (previously presented):

The method of claim 1 wherein the photosensitizer drug is a naturally occurring porphyrin induced by an amino-levulinic acid, an amino-levulinic acid ester, an amino-levulinic amide, or derivatives thereof.

Claim 59 - (previously presented):

The method of claim 1 wherein the intravascular photoactivating light is delivered approximately two minutes to forty-eight hours after the administration of the photosensitizer drug.

Claim 60 - (previously presented):

The method of claim 1 wherein the treatment stabilizes or causes a reduction in size of atherosclerotic vulnerable plaques that can result in vessel occlusion if left untreated.